CN103127090A - Application of Aphanamixoid A in medicines curing kidney cancer - Google Patents
Application of Aphanamixoid A in medicines curing kidney cancer Download PDFInfo
- Publication number
- CN103127090A CN103127090A CN2012104145640A CN201210414564A CN103127090A CN 103127090 A CN103127090 A CN 103127090A CN 2012104145640 A CN2012104145640 A CN 2012104145640A CN 201210414564 A CN201210414564 A CN 201210414564A CN 103127090 A CN103127090 A CN 103127090A
- Authority
- CN
- China
- Prior art keywords
- aphanamixoid
- kidney cancer
- medicines
- application
- renal carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses application of Aphanamixoid A in medicines curing kidney cancer and belongs to the medicines new use technical field. An external MTT antineoplastic activity evaluation shows that the Aphanamixoid A further has evident inhibiting effect on growth of human kidney cancer cell strain KC. Therefore, the Aphanamixoid A can be used for preparing kidney cancer resisting medicines, and has good development and application prospect. Due to the fact that use of the Aphanamixoid A in preparation of the medicines curing the kidney cancer is made public for the first time, and the skeleton type is completely novel, the Aphanamixoid A has an unexpectedly high kidney cancer inhibitory activity.
Description
Technical field
The present invention relates to the new purposes of compd A phanamixoid A, relate in particular to the application of Aphanamixoid A in the anti-renal carcinoma medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in antitumor drug, is exactly the reasonable antitumor drug of effect clinically at present as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
the compd A phanamixoid A that the present invention relates to is one and delivered (Cai in 2012, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.) New skeleton compound, this compound has brand-new framework types, present purposes only relates to insect antifeedant activity (Cai, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.), belong to open first for the purposes of the Aphanamixoid A that the present invention relates in preparation treatment renal carcinoma medicine, because framework types belongs to brand-new framework types, and its inhibition for kidney cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, the control that is used for simultaneously renal carcinoma obviously has significant progress.
Summary of the invention
The invention provides the application of compd A phanamixoid A in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Aphanamixoid A in the anti-renal carcinoma medicine of preparation, and the structural formula of Aphanamixoid A is as shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Aphanamixoid A also has significant inhibitory action to the growth of human renal carcinoma cell strain KC, suppresses the IC of this 1 strain Growth of Cells
50Value is respectively 0.23 ± 0.06 μ M.Therefore, Aphanamixoid A can for the preparation of anti-renal carcinoma medicine, have good development prospect.
The purposes of the Aphanamixoid A that the present invention relates in preparation treatment renal carcinoma medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for kidney cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously renal carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compd A phanamixoid A involved in the present invention is referring to document (Cai, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compd A phanamixoid A tablet involved in the present invention:
Get 20 and digest compound Aphanamixoid A, add conventional adjuvant 180 grams that prepare tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compd A phanamixoid A capsule involved in the present invention:
Get 20 and digest compound Aphanamixoid A, add the conventional adjuvant such as starch 180 grams that prepare capsule, mixing is encapsulatedly made 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Aphanamixoid A to the growth inhibited effect of human renal carcinoma cell strain
1. method: the cell that is in the growth logarithmic (log) phase: human renal carcinoma cell strain KC(buys from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, 0.01 μ M, 0.001 μ M, the culture medium of the Aphanamixoid A of 0.0001 μ M and 0.00001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Aphanamixoid A has significant inhibitory action to the growth of human renal carcinoma cell strain KC.This compound suppresses the IC of human renal carcinoma cell strain KC growth
50Value is respectively: 0.23 ± 0.06 μ M.
Shown by above-described embodiment, Aphanamixoid A of the present invention has good inhibitory action to the growth of human renal carcinoma cell strain KC.Prove thus, it is active that Aphanamixoid A of the present invention has anti-renal carcinoma, can be for the preparation of anti-renal carcinoma medicine.
Claims (1)
1.Aphanamixoid the application of A in treatment renal carcinoma medicine, described compd A phanamixoid A structure is as shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104145640A CN103127090A (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A in medicines curing kidney cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104145640A CN103127090A (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A in medicines curing kidney cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103127090A true CN103127090A (en) | 2013-06-05 |
Family
ID=48487965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104145640A Pending CN103127090A (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A in medicines curing kidney cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127090A (en) |
-
2012
- 2012-10-25 CN CN2012104145640A patent/CN103127090A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| CAI, J. Y. ET AL: "Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya", 《ORGANIC LETTERS》 * |
| 夏菠等: "类柠檬苦素的生物活性研究进展", 《农业品加工（学刊）》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103127091A (en) | Application of Aphanamixoid A in medicines curing colorectal cancer | |
| CN102872135B (en) | Application of Houttuynoid D in drug for treating renal cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102895224A (en) | Application of Aphanamixoid A in drugs for treating breast cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102872144B (en) | Application of Houttuynoid D in drug for treating bladder cancer | |
| CN102872010B (en) | Application of Aphanamixoid A in drugs for treating ovarian cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN103127090A (en) | Application of Aphanamixoid A in medicines curing kidney cancer | |
| CN103127080A (en) | Application of Aphanamixoid A in medicines curing skin cancer | |
| CN103127074A (en) | Application of Aphanamixoid A to ileocecum cancer treatment medicine | |
| CN103120682A (en) | Application of Aphanamixoid A in medicine for treating bladder cancer | |
| CN103120679A (en) | Application of Aphanamixoid A in medicine for treating tongue cancer | |
| CN103120684A (en) | Application of Aphanamixoid A in medicine for treating endometrial carcinoma | |
| CN103462971A (en) | Application of Incarviatone A in medicaments for treating kidney cancer | |
| CN103405454A (en) | Application of Chukrasone A in medicaments for treating renal carcinoma | |
| CN103405423A (en) | Application of Chukrasone B in medicine for treating renal cancer | |
| CN103120680A (en) | Application of Aphanamixoid A in medicine for treating nasopharyngeal carcinoma | |
| CN102861051A (en) | Application of Houttuynoid A in medicine for treating renal cancer | |
| CN102872102A (en) | Application of Houttuynoid C in medicine for treating breast cancer | |
| CN103127079A (en) | Application of Aphanamixoid A in medicines curing stomach cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130605 |